Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens.
ICR mice were immunized intraperitoneally with two doses (10(6) PFU per dose) of vaccinia virus (VV) recombinants of variable virulence expressing either the strongly immunogenic glycoprotein E (gE) of varicella zoster virus (VZV) or weakly immunogenic hepatitis B virus (HBV) preS2-S (S) antigen. Recombinants expressing gE were able to elicit primary and secondary anti-gE antibody irrespective of their residual virulence; after the second dose they did so even in the presence of VV antibody resulting from primary vaccination dose or under other conditions limiting VV replication. As for the S-recombinants, pronounced anti-S antibody development was only observed in mice which had received the more virulent recombinant virus as the first dose. A repeated dose of S-recombinants was unable to elicit a secondary anti-S antibody response. The present findings do not support the assumption that the poor immunogenicity of some extrinsic antigens could be overcome by administering repeated doses of the particular VV recombinant.
Kutinová
L
L
Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Ludvíková
V
V
Nemecková
S
S
Hainz
P
P
Simonová
V
V
Vonka
V
V
D000375:Aging / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D002642:Chick Embryo; D005260:Female; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D007117:Immunization, Secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011498:Protein Precursors / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity*; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C070916:glycoprotein IV, varicella-zoster virus; C050807:presurface protein 2, hepatitis B surface antigen